“…Our findings regarding the costs of IHC raise the question if its routine use is a cost-effective strategy. Bethune et al suggested that the shift towards selective use of IHC in breast cancer patients, instead of routine use, resulted in decreased ITC detection but at the same time led to significant cost savings [24]. In their cohort the rate of macrometastasis and micrometastasis remained equal.…”